Lewis K, Maio M, Demidov L, et al. BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma. ESMO 2017, abstract LBA7_PR.
Adjuvant ipilimumab bij stadium III-melanoom
jan 2017 | Dermato-oncologie, Immuuntherapie